AbbVie acquires Botox-maker Allergan in ‘turning point’ deal

Published: 15-May-2020

The acquisition will see AbbVie achieve approximately US$30bn in full-year 2020 revenues

You need to be a subscriber to read this article.
Click here to find out more.

AbbVie, the biopharmaceutical company, has acquired Allergan in what its CEO described as an “important milestone”.

The acquisition includes Allergan’s global aesthetics

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.

Subscribe now Already a subscriber? Sign in here.

You may also like